NSE · Healthcare · Drug Manufacturers - General
EPS came in at 3.47 against a street estimate of 3.30 — a beat of 5.2%.
with an average price target of ₹324.33.
CONFIDENT Marksans delivered record Q1 FY27 revenue of INR 841 crores (+35.6% YoY) with highest-ever EBITDA of INR 213 crores and PAT of INR 159 crores. Europe grew 74.7% YoY driven by QliniQ acquisition and organic U.K. growth. Management maintains conservative guidance but signals INR 4,000 crore revenue target within 2 years. Q1 FY27 Europe now material growth driver with two acquisitions (QliniQ, ABCnow) establishing direct presence. U.S. remains largest market; Australia growing strongly. Rest of World hampered by geopolitical headwinds. Analysts pressed on gross margin sustainability, Europe acquisition strategy, and U.S. tariff risk. Management acknowledged 59.1% margin unsustainable, outlined 55–56% normalized range, confirmed Europe acquisition pipeline active, and deferred tariff impact pending policy changes. Pushed back on index investing cash use, citing acquisition-focused …
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call MARKSANS PHARMA LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue: INR 840.8 crores, up 35.6% year-on-year (vs INR 620 crores in Q1 FY26) • EBITD | 2026-08-20 |
| Quarterly results · Q1 FY27 MARKSANS PHARMA LTD - DOCUMENT SUMMARY HEADLINE NUMBERS • Document is a regulatory notification dated August 13, 2026 • Company has uploaded audio r | 2026-08-13 |
| Investor presentation · Q1 FY27 MARKSANS PHARMA LTD — Q1FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue: ₹840.8 cr, up 35.6% YoY (Q1FY26: ₹620 cr); flat -1.8% QoQ (Q4FY26: ₹856.1 | 2026-08-12 |
| Annual report FY2026 MARKSANS PHARMA LTD - ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Total Revenue: ₹3,033 crores - exceeded ₹3,000 crore mark for first time • | 2026-08-04 |
| Quarterly results · Q4 FY26 MARKSANS PHARMA LTD – FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from operations (FY 2025-26): ₹13,414.76 million vs ₹11,743.74 million (FY 2024-2 | 2026-06-26 |
| Q4 FY26 earnings call MARKSANS PHARMA LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • FY26 operating revenue: INR 2,951 crores (up 12.5% year-on-year from INR 2,623 crores) | 2026-06-03 |
| Investor presentation · Q4 FY26 MARKSANS PHARMA LTD – Q4 & FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Total Income: ₹3,033 crore (12.8% YoY growth) • FY26 EBITDA: ₹601 crore at | 2026-05-26 |
| Q3 FY26 earnings call MARKSANS PHARMA LTD. – Q3 FY26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q3 FY26 operating revenue: INR 754.4 crores (10.6% YoY growth) – all- | 2026-02-12 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.90 / share ex-date Aug 20, 2026 | 2026-08-20 |
| Announcement | Date |
|---|---|
| Acquisition of 100 percent share capital of ABCnow GmbH Marksans Pharma Limited has informed the Exchange about acquisition of 100 percent share capital of ABCnow GmbH. | 2026-07-20 |
| Signed definitive agreement to acquire 100% stake in German company Marksans Pharma Limited has signed a definitive agreement to acquire 100% of ABCnow GmbH, a German-based company. This is a full acquisition where Marksans will gain complete ownership and c | 2026-07-08 |
| Update on acquisition of QliniQ B.V. Marksans Pharma Limited has informed the Exchange about Update on acquisition of QliniQ B.V. | 2026-06-16 |
| Acquires 100% of Netherlands-based QliniQ B.V. for European expansion Marksans Pharma Limited announced the acquisition of 100% stake in QliniQ B.V., a Netherlands-based pharmaceutical company. This is a strategic move to expand the company's presence in Europ | 2026-06-01 |
| FY2026 net income guidance of ₹3,000 Cr delivered; record revenue, EBITDA, PAT Marksans Pharma Limited announced record-breaking financial performance for the period ending May 26, 2026. The company achieved its highest-ever revenue, EBITDA (earnings before interest, t | 2026-05-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Marksans Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.